Cryptococcal Meningitis Screening and Community-based Early Adherence Support in People With Advanced Human Immunodeficiency Virus Infection Starting Antiretroviral Therapy in Tanzania and Zambia: A Cost-effectiveness Analysis.
Africa
HIV late-stage disease
adherence support
cost-effectiveness
cryptococcal meningitis
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
10 04 2020
10 04 2020
Historique:
received:
22
02
2019
accepted:
30
05
2019
pubmed:
1
6
2019
medline:
7
1
2021
entrez:
1
6
2019
Statut:
ppublish
Résumé
A randomized trial demonstrated that among people living with late-stage human immunodeficiency virus (HIV) infection initiating antiretroviral therapy, screening serum for cryptococcal antigen (CrAg) combined with adherence support reduced all-cause mortality by 28%, compared with standard clinic-based care. Here, we present the cost-effectiveness. HIV-infected adults with CD4 count <200 cells/μL were randomized to either CrAg screening plus 4 weekly home visits to provide adherence support or to standard clinic-based care in Dar es Salaam and Lusaka. The primary economic outcome was health service care cost per life-year saved as the incremental cost-effectiveness ratio (ICER), based on 2017 US dollars. We used nonparametric bootstrapping to assess uncertainties and univariate deterministic sensitivity analysis to examine the impact of individual parameters on the ICER. Among the intervention and standard arms, 1001 and 998 participants, respectively, were enrolled. The annual mean cost per participant in the intervention arm was US$339 (95% confidence interval [CI], $331-$347), resulting in an incremental cost of the intervention of US$77 (95% CI, $66-$88). The incremental cost was similar when analysis was restricted to persons with CD4 count <100 cells/μL. The ICER for the intervention vs standard care, per life-year saved, was US$70 (95% CI, $43-$211) for all participants with CD4 count up to 200 cells/μL and US$91 (95% CI, $49-$443) among those with CD4 counts <100 cells /μL. Cost-effectveness was most sensitive to mortality estimates. Screening for cryptococcal antigen combined with a short period of adherence support, is cost-effective in resource-limited settings.
Sections du résumé
BACKGROUND
A randomized trial demonstrated that among people living with late-stage human immunodeficiency virus (HIV) infection initiating antiretroviral therapy, screening serum for cryptococcal antigen (CrAg) combined with adherence support reduced all-cause mortality by 28%, compared with standard clinic-based care. Here, we present the cost-effectiveness.
METHODS
HIV-infected adults with CD4 count <200 cells/μL were randomized to either CrAg screening plus 4 weekly home visits to provide adherence support or to standard clinic-based care in Dar es Salaam and Lusaka. The primary economic outcome was health service care cost per life-year saved as the incremental cost-effectiveness ratio (ICER), based on 2017 US dollars. We used nonparametric bootstrapping to assess uncertainties and univariate deterministic sensitivity analysis to examine the impact of individual parameters on the ICER.
RESULTS
Among the intervention and standard arms, 1001 and 998 participants, respectively, were enrolled. The annual mean cost per participant in the intervention arm was US$339 (95% confidence interval [CI], $331-$347), resulting in an incremental cost of the intervention of US$77 (95% CI, $66-$88). The incremental cost was similar when analysis was restricted to persons with CD4 count <100 cells/μL. The ICER for the intervention vs standard care, per life-year saved, was US$70 (95% CI, $43-$211) for all participants with CD4 count up to 200 cells/μL and US$91 (95% CI, $49-$443) among those with CD4 counts <100 cells /μL. Cost-effectveness was most sensitive to mortality estimates.
CONCLUSIONS
Screening for cryptococcal antigen combined with a short period of adherence support, is cost-effective in resource-limited settings.
Identifiants
pubmed: 31149704
pii: 5509363
doi: 10.1093/cid/ciz453
pmc: PMC7146002
doi:
Substances chimiques
Antigens, Fungal
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1652-1657Subventions
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
BMC Public Health. 2009 Aug 11;9:290
pubmed: 19671185
J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):221-5
pubmed: 22820805
Clin Infect Dis. 2016 Mar 1;62(5):581-587
pubmed: 26565007
BMC Public Health. 2014 Mar 31;14:296
pubmed: 24684772
J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):e101-8
pubmed: 23466647
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):e69-76
pubmed: 25761234
Clin Infect Dis. 2010 Aug 15;51(4):448-55
pubmed: 20597693
PLoS Med. 2017 Oct 2;14(10):e1002397
pubmed: 28968399
J Int AIDS Soc. 2012 Nov 19;15(2):17383
pubmed: 23199799
Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192
pubmed: 15544708
J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):e25-32
pubmed: 22895437
Med Care. 2009 Jul;47(7 Suppl 1):S76-81
pubmed: 19536026
Lancet Infect Dis. 2017 Aug;17(8):873-881
pubmed: 28483415
AIDS. 2008 Oct 1;22(15):1897-908
pubmed: 18784453
BMC Infect Dis. 2010 Mar 15;10:67
pubmed: 20230635
PLoS One. 2017 Feb 24;12(2):e0171917
pubmed: 28234969
PLoS Med. 2011 Jul;8(7):e1001056
pubmed: 21811403
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S152-S159
pubmed: 29514236
BMC Infect Dis. 2017 Mar 23;17(1):225
pubmed: 28335769
Trop Med Int Health. 2007 Aug;12(8):929-35
pubmed: 17697087
PLoS One. 2014 Jun 20;9(6):e100107
pubmed: 24950185
PLoS One. 2013 Jul 19;8(7):e69288
pubmed: 23894442
Clin Infect Dis. 2020 Jan 1;70(1):26-29
pubmed: 30816418
Ann Intern Med. 2011 Aug 16;155(4):209-16
pubmed: 21768555
PLoS One. 2012;7(12):e51993
pubmed: 23284843
N Engl J Med. 2018 Mar 15;378(11):1004-1017
pubmed: 29539274
Lancet. 2015 May 30;385(9983):2173-82
pubmed: 25765698
PLoS Med. 2011 Jul;8(7):e1001055
pubmed: 21811402
J Int AIDS Soc. 2013 Jan 02;16:18026
pubmed: 23305696